Expert Opinion on Drug Metabolism & Toxicology

Article	Citations
Probing the mechanism of reduced in vivo potency of insulin detemir	113
Comorbidities and the right dose: antipsychotics	106
The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update	68
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects	60
Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata	57
The Central Role of Cytochrome P450 Reductase (CPR) in Hyperoxic Lung Injury	50
Hormones, microbes, and PrEP drugs in the female genital tract	45
Guidance for interactions between antiseizure medications	32
Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis	32
An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria	27
Azole antifungals and inter-individual differences in drug metabolism: the role of pharmacogenomics and precision medicine	27
A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database	25
Pharmacokinetics and pharmacodynamics of approved monoclonal antibody therapy for colorectal cancer	23
Immune-mediated liver injury caused by immune checkpoint inhibitors exhibits distinct clinical features that differ from autoimmune hepatitis	23
Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update	21
In NAMs we trust – an innovative paradigm-shift in risk-based chemicals management for globally harmonized protection goals	20
The safety and toxicity profile of SPL84, an inhaled antisense oligonucleotide for treatment of cystic fibrosis patients with the 3849 +10kb C->T mutation, supports a Phase 1/2 clinical study	19
Current status and future perspectives on the use of therapeutic drug monitoring of thiopurine metabolites in patients with inflammatory bowel disease	19
Respiratory aspiration during treatment with clozapine and other antipsychotics: a literature search and a pharmacovigilance study in vigibase	19
Pharmacokinetic and toxicodynamic concepts in idiosyncratic, drug-induced liver injury	19
Bioactivity descriptors for in vivo toxicity prediction: now and the future	18
A comprehensive review of the efficacy and safety of ertugliflozin	17
Correction	17
Respiratory aspiration during treatment with benzodiazepines, antiepileptic and antidepressant drugs in the pharmacovigilance database from VigiBase	17
A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition	17

Drug-drug interactions between psychotropic medications and oral contraceptives	16
Clinical pharmacokinetics and pharmacodynamics of nicardipine; a systematic review	16
Physiologically based pharmacokinetic modeling in obesity: applications and challenges	15
Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	15
Population pharmacokinetics of olanzapine in pediatric patients with psychiatric disorders	15
Pharmacokinetic considerations surrounding triple therapy for uncontrolled asthma	15
A high-throughput liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of p -cresol sulfate, p -cresol	14
Pharmacokinetic considerations surrounding the use of levetiracetam for seizure prophylaxis in neurocritical care – an overview	14
The impact of advanced age on anticoagulant therapy for acute venous thromboembolism	13
Risk factors and prediction for DILI in clinical practice	12
Evaluating pharmacokinetic drug–drug interactions of direct oral anticoagulants in patients with renal dysfunction	12
Population pharmacokinetic–pharmacodynamic analysis of givinostat	12
Current state-of-the-art approaches for mass spectrometry in clinical toxicology: an overview	12
Integrative approaches for studying the role of noncoding RNAs in influencing drug efficacy and toxicity	12
Drug absorption from oral formulations in patients with short bowel syndrome: a comprehensive update of the literature	12
Rezafungin acetate for the treatment of candidemia and invasive candidiasis: a pharmacokinetic evaluation	12
Recent progress in machine learning approaches for predicting carcinogenicity in drug development	12
Therapeutic drug monitoring of clozapine in adults with schizophrenia: a review of challenges and strategies	11
Effect of oral semaglutide on the pharmacokinetics of thyroxine after dosing of levothyroxine and the influence of co-administered tablets on the pharmacokinetics of oral semaglutide in healthy subjec	11
Regulation of carboxylesterases and its impact on pharmacokinetics and pharmacodynamics: an up-to-date review	11
The use of glucarpidase as a rescue therapy for high dose methotrexate toxicity – a review of pharmacological and clinical data	11
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarction	10
CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study	10
Development and application of a population pharmacokinetic model repository for caffeine dose tailoring in preterm infants	10
Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes	9
In-silico approaches to assessing multiple high-level drug-drug and drug-disease adverse drug effects	9
Pharmacodynamics of Janus kinase inhibitors for the treatment of atopic dermatitis	9
Switching from cangrelor to oral P2Y 12 inhibitors: a focused review on drug–drug interactions	9
An evaluation of the pharmacokinetics of inclisiran in the treatment of atherosclerotic cardiovascular disease	9
Bioequivalence of generic and branded ibrutinib capsules in healthy Chinese volunteers under fasting and fed conditions: a randomized, four-period, fully replicated, crossover study	9
The oral GnRH antagonists, a new class of drugs in gynecology: from pharmacokinetics to possible clinical applications	9
Analysis of drug–drug interactions in patients with HIV and metabolic syndrome	9
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion	9
PBPK models of the female reproductive tract: current and future analysis	9
Evaluating the utility of therapeutic drug monitoring in the clinical use of small molecule kinase inhibitors: a review of the literature	9
Safety of concomitant use of oral anticoagulants and antidiabetic drugs: a systematic review of observational studies	9
Optimizing antibiotic dosing regimens for nosocomial pneumonia: a window of opportunity for pharmacokinetic and pharmacodynamic modeling	9
Pharmacokinetic considerations for community-based dosing of nasal naloxone in opioid overdose in adults	8
Cardiomyocyte-specific CYP2J2 and its therapeutic implications	8
Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention	8
Clinical pharmacokinetics of levodopa and relevant add-on therapies for Parkinson’s disease	8
Overcoming barriers to machine learning applications in toxicity prediction	8
Positioning the new drugs for migraine	8
Identification of genetic biomarkers associated with pharmacokinetics and pharmacodynamics of apixaban in Chinese healthy volunteers	8
High-throughput PBTK models for in vitro to in vivo extrapolation	8
Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids	7
Machine learning and deep learning approaches for enhanced prediction of hERG blockade: a comprehensive QSAR modeling study	7
Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer’s disease lead to depression?	7
Drug interactions in people with HIV treated with antivirals for other viral illnesses	7
CYP2D6 pharmacogenetics and phenoconversion in personalized medicine	7

The role of pharmacogenetics in the treatment of anxiety disorders and the future potential for targeted therapeutics	7
Toxic metabolites and metabolic soft spots of celastrol based on glutathione metabolic capture and high-resolution mass spectrometry	7
Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healt	7
Drug-drug interactions involving CFTR modulators: a review of the evidence and clinical implications	7
Regulation of cyclophosphamide induced hepatotoxicity by REV-ERBα modifiers	6
Drug–drug interactions in HIV-infected patients receiving chemotherapy	6
Overview of the pharmacokinetics and pharmacodynamics of URAT1 inhibitors for the treatment of hyperuricemia and gout	6
Managing intoxications with nicotine-containing e-liquids	6
DILI prediction in drug development: present and future	6
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage	6
Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study	6
The influence of pharmacodynamics and pharmacokinetics on the antimigraine efficacy and safety of novel anti-CGRPergic pharmacotherapies: a narrative review	6
Recent progress in adverse events of carboxylic acid non-steroidal anti-inflammatory drugs (CBA-NSAIDs) and their association with the metabolism: the consequences on mitochondrial dysfunction and oxi	6
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability	6
Pharmacokinetic studies in dialysis-dependent patients: limited data availability	6
Cytotoxic activity of KRAS inhibitors in combination with chemotherapeutics	6
Drug dosing optimization in critically ill children under continuous renal replacement therapy: from basic concepts to the bedside model informed precision dosing	6
Considerations for drug–drug interactions between long-acting antiretrovirals and immunosuppressants for solid organ transplantation	6
Genetic variation in organic cation transporters and considerations in drug development	5
Understanding the impact of ABCG2 polymorphisms on drug pharmacokinetics: focus on rosuvastatin and allopurinol	5
Acetaminophen toxicity and overdose: current understanding and future directions for NAC dosing regimens	5
Cardiometabolic complications in children and adolescents with HIV on antiretroviral therapy	5
How can we better address the pharmacokinetics of antipsychotics in children and adolescents?	5
Drug–drug interactions involving antipsychotics and antihypertensives	5
A fresh look at proton pump inhibitor (PPI)-associated adverse events through a CYP2C19 pharmacogenetic lens	5
Optimizing drug therapy during pregnancy: a spotlight on population pharmacokinetic modeling	5
The impact of menstrual cycle on the pharmacokinetics of antiseizure medications and lithium: a systematic review and meta-analysis	5
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?	5
Pharmacokinetics and pharmacodynamics of antibody-drug conjugates for the treatment of patients with breast cancer	5
A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database	5
Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation	5
Strategies for the treatment of acute benzodiazepine toxicity in a clinical setting: the role of antidotes	5
Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review	5
Interindividual variability in statin pharmacokinetics and effects of drug transporters	5
Metabolic and toxicological considerations of Bruton’s tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma	5
Pharmacokinetic characteristics of risperidone ISM for the treatment of schizophrenia	5
Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond	4
Individualizing doses of antiepileptic drugs	4
Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs	4
Understanding mechanisms of drug resistance in epilepsy and strategies for overcoming it	4
In vitro neurotoxicity testing: lessons from chemotherapy-induced peripheral neurotoxicity	4
Cutaneous toxicity of FDA-approved small-molecule kinase inhibitors	4
In silico prediction of drug-induced nephrotoxicity: current progress and pitfalls	4
Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia	4
CAR-T cell therapies for cancer: what novel technologies are being developed for toxicity data?	4
The Impact of Pregnancy on Antihypertensive Drug Metabolism and Pharmacokinetics: Current Status and Future Directions	4
Ceftriaxone and methicillin-susceptible staphylococcus aureus: a perspective from pharmacokinetics/pharmacodynamics studies	4
A novel in vivo approach to monitoring Cyp3a induction and inhibition by bioluminescent urinalysis	4
Screening tools to evaluate the neurotoxic potential of botanicals: building a strategy to assess safety	4
Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment	4
Cannabidiol: metabolism and clinical efficacy in epileptic patients	4
Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what’s new?	4
Treatment optimization of maintenance immunosuppressive agents in pediatric renal transplant recipients	4
Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis	4
Absorption, distribution, metabolism and excretion of hyaluronic acid during pregnancy: a matter of molecular weight	4
Lessons learned from the influence of CYP2C9 genotype on warfarin dosing	4
Cephalosporins with warfarin increase the risk of bleeding: myth or fact?	4
The impact of sepsis on hepatic drug metabolism in critically ill patients: a narrative review	4
The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events	4
Pharmacokinetic evaluation of cefiderocol for the treatment of multidrug resistant Gram-negative infections	4
Pharmacokinetic review of janus kinase inhibitors and its clinical implications for the management of rheumatoid arthritis	4
Drug pharmacokinetics in the obese population: challenging common assumptions on predictors of obesity-related parameter changes	4
Transporters and drug secretion into human breast milk	4
Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach	3
Sex-specific UGT expression and function: prevalence, potential mechanisms and significance	3
Evaluating the pharmacokinetic and pharmacodynamic impact of different modes of ticagrelor administration	3
Current opinion on the pharmacogenomics of paclitaxel-induced toxicity	3
The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?	3
Comparison of pharmacokinetic properties of alteplase and tenecteplase. The future of thrombolysis in acute ischemic stroke	3
Sex-gender differences in pharmacokinetics	3
Machine learning models in the prediction of drug metabolism: challenges and future perspectives	3
What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?	3
Improving on in-silico prediction of oral drug bioavailability	3
Beyond animal models: implementing the 3Rs principles and improving pharmacological studies with new model systems	3
Exposure to antibiotics during pregnancy alters offspring outcomes	3
A critical review of methotrexate clinical interactions: role of transporters	3
Milvexian, a novel factor XIa inhibitor for stroke prevention: pharmacokinetic and pharmacodynamic evaluation	3
What is the most effective and safest Non-steroidal anti-inflammatory drug for treating osteoarthritis in patients with comorbidities?	3
Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies	3
Pharmacokinetics and pharmacodynamics of angiogenesis inhibitors used to treat cervical cancer: current and future	3

A repeat-dose toxicity study of human umbilical cord mesenchymal stem cells in NOG mice by intravenous injection	3
JAK1 inhibitors for the treatment of atopic dermatitis: a focus on pharmacokinetic considerations	3
Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older	3
Overcoming the shortcomings of the extended-clearance concept: a framework for developing a physiologically-based pharmacokinetic (PBPK) model to select drug candidates involving transporter-mediated	3
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia	3
Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy	3
The mysteries of target site concentrations of antibiotics in bone and joint infections: what is known? A narrative review	3
Gut microbiota-drug interactions in cancer pharmacotherapies: implications for efficacy and adverse effects	3
Inositols in the ovaries: activities and potential therapeutic applications	3
Organotypic-liver slide culture systems to explore the role of extracellular vesicles in pancreatic cancer metastatic behavior and guide new therapeutic approaches	2
Impact of pediatric continuous renal replacement therapy parameters on meropenem, piperacillin, and tazobactam pharmacokinetics: an in vitro model	2
Metabolic and toxicological considerations regarding CGRP mAbs and CGRP antagonists to treat migraine in COVID-19 patients: a narrative review	2
Development and evaluation of a physiologically based pharmacokinetic model to predict carvedilol-paroxetine metabolic drug–drug interaction in healthy adults and its extrapolation to virtual chronic	2
Effects of obesity on the pharmacology of proton pump inhibitors: current understanding and future implications for patient care and research	2
Potential and real drug interactions in patients treated with abiraterone or enzalutamide in clinical practice	2
Modeling drug-induced liver injury: current status and future prospects	2
The impact of CBR3 (rs1056892) and ABCC1 (rs45511401) genetic polymorphisms on doxorubicin-induced cardiotoxicity and the potential role of brain natriuretic peptide as an early cardiac biomarker in b	2
An update on the pharmacogenetic considerations when prescribing dopamine receptor agonists for Parkinson’s disease	2
Safety of medicines during breastfeeding – from case report to modeling: a contribution from the ConcePTION project	2
Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil	2
A systematic review on the clinical pharmacokinetics of vildagliptin in healthy and disease populations	2
Drug-induced liver injury associated with the use of newer antiseizure medications in the elderly: an analysis of data from VigiBase	2
Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease	2
Pharmacogenetic guided drug therapy – how to deal with phenoconversion in polypharmacy	2
Epigenetics is involved in the pleiotropic effects of statins	2
Strategies for the prevention and treatment of bleeding in patients treated with dabigatran: an update	2
The quest to define cancer-specific systems parameters for personalized dosing in oncology	2
Toward regulatory acceptance and improving the prediction confidence of in silico approaches: a case study of genotoxicity	2
Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis	2
Combined oral contraceptive with estetrol plus drospirenone: from pharmacokinetics to clinical applications	2
Local anesthetics and erector spinae plane blocks: a spotlight on pharmacokinetic considerations and toxicity risks	2
Therapeutic drug monitoring of TNFα inhibitors: a spotlight on novel techniques and assays	2
Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment	2
Optimizing therapeutic drug monitoring in inflammatory bowel disease: a focus on therapeutic monoclonal antibodies	2
Pharmacokinetics, pharmacodynamics, safety, and tolerability of dopamine-receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting	2
Update on drug-drug interaction at organic cation transporters: mechanisms, clinical impact, and proposal for advancedin vitrotesting	2
Polymorphisms of genes related to phase-I metabolic enzymes affecting the clinical efficacy and safety of clopidogrel treatment	2
Where developmental toxicity meets explainable artificial intelligence: state-of-the-art and perspectives	2
Potential drug-drug interaction between sodium-glucose co-transporter 2 inhibitors and statins: pharmacological and clinical evidence	2
The relationship between CYP2C9 gene polymorphisms and azilsartan metabolism in vitro	2
How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives	2
Preventable serious drug-disease interactions of reserve antibiotics	2
The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions	2
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse	2
Enhancing drug-drug Interaction Prediction by Integrating Physiologically-Based Pharmacokinetic Model with Fraction Metabolized by CYP3A4	2
Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerations	2
Drug-drug interactions between COVID-19 therapeutics and psychotropic medications	2
Personalization of drug dose thematic issue: introduction article	2
Current and future physiologically based pharmacokinetic (PBPK) modeling approaches to optimize pharmacotherapy in preterm neonates	2